Cartesian Therapeutics, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

C Andrew Stewart

Murat V Kalayoglu

Michael S Singer

Metin Kurtoglu

Yi Zhang

Nadya Tarasova

Alan O Perantoni

Howard A Young

Marco A Cardone

Giorgio Trinchieri

Nadya I Tarasova

Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

Anti-BCMA chimeric antigen receptors

A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.

Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling

Growing community of inventors

Frederick, MD, United States of America

C Andrew Stewart